Highlights of This Issue

SMALL MOLECULE THERAPEUTICS

3 Repurposing the Antihelmintic Mebendazole as a Hedgehog Inhibitor
Andrew R. Larsen, Ren-Yuan Bai, Jon H. Chung, Alexandra Borodovsky, Charles M. Rudin, Gregory J. Riggins, and Fred Bunz

14 TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
Shuichi Ohkubo, Yasuo Kodama, Hiromi Muraoka, Hiroko Hiotsumachi, Chihoko Yoshimura, Makoto Kitade, Akiko Hashimoto, Kenjiro Ito, Akira Gomori, Koichi Takahashi, Yoshihiro Shibata, Akira Kanoh, and Kazuhiro Yonekura

23 Darinaparsin Inhibits Prostate Tumor–Initiating Cells and Du145 Xenografts and Is an Inhibitor of Hedgehog Signaling
Nitu Bansal, Nadine Johnson Farley, Lisa Wu, Jonathan Lewis, Hagop Youssoufian, and Joseph R. Bertino

31 Preclinical Characterization of RSM-932A, a Novel Anticancer Drug Targeting the Human Choline Kinase Alpha, an Enzyme Involved in Increased Lipid Metabolism of Cancer Cells
Juan Carlos Lacal and Joaquín M. Campos

40 Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer
Melissa R. Junttila, Vidusha Devasthali, Jason H. Cheng, Joseph Castillo, Ciara Metcalfe, Anne C. Clermont, Douglas Den Otter, Emily Chan, Hani Bou-Reslan, Tim Cao, William Forrest, Hannah Dry, Claire Crafer, Bernard Barlaam, Martin Fitzek, Paul D. Smith, Emily Foster, Marie Cumberbatch, Simon T. Barry

59 Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
Paul J. Toren, Soojin Kim, Steven Pham, Azza Mangalji, Hans Adomat, Emma S. Tomlinson Guns, Amina Zoubi, William Moore, and Martin Gleave

70 Radioprotection of the Brain White Matter by Mn(III) N-Butoxyethylpyridylporphyrin–Based Superoxide Dismutase Mimic MnTnBuOE-2-PyP5+

80 Small Molecule Inhibitor YM155-Mediated Activation of Death Receptor 5 Is Crucial for Chemotherapy-Induced Apoptosis in Pancreatic Carcinoma
Xianguan Zhao, William M. Puzyk, Zaiming Lu, David A. Ostrov, Thomas J. George, Keith D. Robertson, and Chen Liu

90 The Protein Phosphatase 2A Inhibitor LB100 Sensitizes Ovarian Carcinoma Cells to Cisplatin-Mediated Cytotoxicity
Ki-Eun Chang, Bih-Rong Wei, James P. Madigan, Matthew D. Hall, R. Mark Simpson, Zhengqing Zhuang, and Michael M. Gottesman

101 Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models
Eric Ciamporcero, Kiersten Marie Miles, Remi Adelaiye, Swayth Ramakrishnan, Li Shen, ShengYu Ku, Stefania Pizzimenti, Barbara Sennino, Giuseppina Arrera, and Roberto Pili

111 Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
Yulian P. Ramirez, Ann C. Mladek, Roger M. Phillips, Mikko Gynther, Jarkko Rautio, Alonzo H. Ross, Richard T. Wheelhouse, and Jann N. Sakaria
120 Tumor-Penetrating iRGD Peptide Inhibits Metastasis
Kazuki N. Sugahara, Gary B. Braun, Tatiana Hurtado de Mendoza, Venkata Ramana Kotamraju, Randall P. French, Andrew M. Lowy, Tambet Teesalu, and Erkki Ruoslahti

141 Near Infrared Photoimmunotherapy in the Treatment of Disseminated Peritoneal Ovarian Cancer
Kazuhide Sato, Hirofumi Hanaoka, Rira Watanabe, Takahito Nakajima, Peter L. Choyke, and Hisataka Kobayashi

151 Bicyclic Peptides Conjugated to an Albumin-Binding Tag Diffuse Efficiently into Solid Tumors
Lisa Pollaro, Sandeep Raghunathan, Julia Morales-Sanfrutos, Alessandro Angelini, Stephan Kontos, and Christian Heinis

174 Combined CDKN1A/TP53 Mutation in Bladder Cancer Is a Therapeutic Target
Yang Liu and David J. Kwiatkowski

202 Direct Binding of Arsenic Trioxide to AMPK and Generation of Inhibitory Effects on Acute Myeloid Leukemia Precursors

213 Midkine Lacking Its Last 40 Amino Acids Acts on Endothelial and Neuroblastoma Tumor Cells and Inhibits Tumor Development
Noushin Dianat, Barbara Le Viet, Emilie Gobbo, Nathalie Auger, Ivan Bèche, Amelie Bemacere-Griscelli, and Frank Griscelli

225 ANP63α Transcriptionally Activates Chemokine Receptor 4 (CXCR4) Expression to Regulate Breast Cancer Stem Cell Activity and Chemotaxis
Andrew J. DeCastro, Pratima Cherukuri, Amanda Balboni, and James DiRienzo

236 Interactions of Multitargeted Kinase Inhibitors and Nucleoside Drugs: Achilles Heel of Combination Therapy?
Vijaya L. Damaraju, Michelle Kuzma, Delores Mowles, Carol E. Cass, and Michael B. Sawyer

246 Elevated IJM Kinase 1 in Nonmetastatic Prostate Cancer Reflects Its Role in Facilitating Androgen Receptor Nuclear Translocation
Katerina Mardilovich, Mads Gabrielsen, Lynn McGarry, Clare Orange, Rachana Patel, Emma Shanks, Joanne Edwards, and Michael F. Olson

259 Enhanced Colonic Tumorigenesis in Alkaline Sphingomyelinase (NPP7) Knockout Mice
Ying Chen, Ping Zhang, Shu-Chang Xu, Liping Yang, Ulrikke Voss, Eva Ekblad, Yunjin Wu, Yalan Min, Erik Hertervig, Åke Nilsson, and Rui-Dong Duan

268 Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression
Feng-qi Nie, Ming Sun, Jin-song Yang, Min Xie, Tong-peng Xu, Rui Xia, Yan-wen Liu, Xiang-hua Liu, Er-bao Zhang, Kai-hua Lu, and Yong-qian Shu
Identifying Actionable Targets through Integrative Analyses of GEM Model and Human Prostate Cancer Genomic Profiling

The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation
Yufeng Hu, Hexiu Su, Xu Li, Guoli Guo, Ling Cheng, Renyi Qin, Guoliang Qing, and Hudan Liu

Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes
Lauren S. Fink, Alexander Beatty, Karthik Devarajan, Suraj Pesi, and Jeffrey R. Peterson

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

Changes in BAI1 and Nestin Expression Are Prognostic Indicators for Survival and Metastases in Breast Cancer and Provide Opportunities for Dual Targeted Therapies
Walter Hans Meisen, Samuel Dubin, Steven T. Sizemore, Hanitha Mathayaraja, Katie Thies, Norman L. Lehman, Peter Boyer, Alena Cristina Jaime-Ramirez, J. Bradley Elder, Kimberly Powell, Arnab Chakravarti, Michael C. Ostrowski, and Balveen Kaur

ABOUT THE COVER
Tumor antigen–targeting mAbs, such as Herceptin, are critical weapons in the cancer therapeutic arsenal, yet they cross the blood–brain barrier (BBB) poorly and their success treating brain tumors is limited. By conjugating an anti-HER2 mAb with a peptide that utilizes receptor-mediated transcytosis across the BBB, a brain-penetrant mAb, ANG4043, was created. ANG4043’s retention of tumor-targeting properties was demonstrated in HER2-positive BT-474 breast carcinoma cells. Colocalization of the control anti-HER2 mAb and the HER2 antigen is shown in yellow on the cell surface. For details, see article by Regina and colleagues on page 129.